Show simple item record

dc.contributor.authorMahmood, RD
dc.contributor.authorShaw, D
dc.contributor.authorDescamps, T
dc.contributor.authorZhou, C
dc.contributor.authorMorgan, RD
dc.contributor.authorMullamitha, S
dc.contributor.authorSaunders, M
dc.contributor.authorMescallado, N
dc.contributor.authorBacken, A
dc.contributor.authorMorris, K
dc.contributor.authorLittle, RA
dc.contributor.authorCheung, S
dc.contributor.authorWatson, Y
dc.contributor.authorO'Connor, JPB
dc.contributor.authorJackson, A
dc.contributor.authorParker, GJM
dc.contributor.authorDive, C
dc.contributor.authorJayson, GC
dc.date.accessioned2021-06-11T11:38:59Z
dc.date.available2021-06-11T11:38:59Z
dc.identifier.citationBMC cancer, 2021, 21 (1), pp. 354 - ?
dc.identifier.issn1471-2407
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/4622
dc.identifier.eissn1471-2407
dc.identifier.eissn1471-2407en_US
dc.identifier.doi10.1186/s12885-021-08097-9
dc.identifier.doi10.1186/s12885-021-08097-9en_US
dc.description.abstractBackground Patients with metastatic colorectal cancer are treated with cytotoxic chemotherapy supplemented by molecularly targeted therapies. There is a critical need to define biomarkers that can optimise the use of these therapies to maximise efficacy and avoid unnecessary toxicity. However, it is important to first define the changes in potential biomarkers following cytotoxic chemotherapy alone. This study reports the impact of standard cytotoxic chemotherapy across a range of circulating and imaging biomarkers.Methods A single-centre, prospective, biomarker-driven study. Eligible patients included those diagnosed with colorectal cancer with liver metastases that were planned to receive first line oxaliplatin plus 5-fluorouracil or capecitabine. Patients underwent paired blood sampling and magnetic resonance imaging (MRI), and biomarkers were associated with progression-free survival (PFS) and overall survival (OS).Results Twenty patients were recruited to the study. Data showed that chemotherapy significantly reduced the number of circulating tumour cells as well as the circulating concentrations of Ang1, Ang2, VEGF-A, VEGF-C and VEGF-D from pre-treatment to cycle 2 day 2. The changes in circulating concentrations were not associated with PFS or OS. On average, the MRI perfusion/permeability parameter, K<sup>trans</sup>, increased in response to cytotoxic chemotherapy from pre-treatment to cycle 2 day 2 and this increase was associated with worse OS (HR 1.099, 95%CI 1.01-1.20, p = 0.025).Conclusions In patients diagnosed with colorectal cancer with liver metastases, treatment with standard chemotherapy changes cell- and protein-based biomarkers, although these changes are not associated with survival outcomes. In contrast, the imaging biomarker, K<sup>trans</sup>, offers promise to direct molecularly targeted therapies such as anti-angiogenic agents.
dc.formatElectronic
dc.format.extent354 - ?
dc.languageeng
dc.language.isoeng
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectHumans
dc.subjectNeoplasm Metastasis
dc.subjectFluorouracil
dc.subjectProspective Studies
dc.subjectAged
dc.subjectFemale
dc.subjectMale
dc.subjectBiomarkers, Tumor
dc.subjectCapecitabine
dc.subjectOxaliplatin
dc.titleEffect of oxaliplatin plus 5-fluorouracil or capecitabine on circulating and imaging biomarkers in patients with metastatic colorectal cancer: a prospective biomarker study.
dc.typeJournal Article
dcterms.dateAccepted2021-03-24
rioxxterms.versionVoR
rioxxterms.versionofrecord10.1186/s12885-021-08097-9
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
dc.relation.isPartOfBMC cancer
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Quantitative Biomedical Imaging
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Quantitative Biomedical Imaging
pubs.publication-statusPublished
pubs.volume21en_US
pubs.embargo.termsNot known
icr.researchteamQuantitative Biomedical Imaging
icr.researchteamQuantitative Biomedical Imagingen_US
dc.contributor.icrauthorO'Connor, James Patricken


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

http://creativecommons.org/licenses/by/4.0/
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by/4.0/